Hepatorenal Syndrome Treatment Global Market Report 2024

The hepatorenal syndrome treatment market has grown strongly in recent years. It will grow from $13.85 billion in 2023 to $14.67 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. The expansion observed in the historical period can be attributed to factors such as the growth of the automotive industry, the requirements of the aerospace sector, advantages in material utilization, improved mechanical properties, adherence to stringent industry standards, and gains in efficiency and precision.

The hepatorenal syndrome treatment market is expected to see strong growth in the next few years. It will grow to $18.56 billion in 2028 at a compound annual growth rate (CAGR) of 6.1%. The anticipated growth in the forecast period can be attributed to factors such as the rise in renewable energy projects, a growing demand for high-performance alloys, a focus on sustainable manufacturing practices, the expansion of oil and gas exploration activities, and the increasing demand for high-performance components. Key trends expected in the forecast period encompass the integration of Industry 4.0 technologies, ongoing research and development in forging techniques, customization tailored for specific applications, automation in forging processes, and innovations in heating and cooling technologies within the industry.

The anticipated increase in the number of patients experiencing liver damage or cirrhosis is expected to drive the growth of the hepatorenal syndrome treatment market in the future. Cirrhosis, a severe form of liver disease characterized by the permanent replacement of healthy liver tissue with scar tissue, underscores the importance of hepatorenal syndrome treatment. The objective of such treatment is to preserve kidney function, alleviate symptoms, and mitigate adverse effects of the disorder, potentially making patients better candidates for liver transplant surgery. For example, in September 2022, the Centers for Disease Control and Prevention reported that the number of adults diagnosed with liver disease in the United States was 4.5 million, highlighting the urgency for effective hepatorenal syndrome treatment as liver-related fatalities increased.

The growth of the hepatorenal syndrome treatment market is further expected to be propelled by the increasing designations of fast-track and novel drugs. These regulatory pathways facilitate the expedited development, review, and approval of drugs for serious conditions with unmet medical needs, aiming to bring innovative therapies to patients more swiftly. The rise in such designations is geared towards accelerating the development of hepatorenal syndrome treatments, addressing the urgent need for effective therapies, improving patient outcomes, and fulfilling unmet medical needs in this condition. For instance, in January 2022, the US Food and Drug Administration designated 36% of the 50 novel drugs in 2021 as having fast-track status, contributing to the growth of the hepatorenal syndrome treatment market.

The anticipated growth in healthcare spending is also expected to drive the expansion of the hepatorenal syndrome treatment market. As the total amount spent on healthcare increases, more funding becomes available for research and development of novel and potent treatments for hepatorenal syndrome. Additionally, increased healthcare spending may lead to greater accessibility to tools for hepatorenal syndrome screening and early detection, potentially resulting in improved outcomes through early treatment. For instance, in February 2023, the US Centers for Medicare & Medicaid Services reported a 2.7% increase in national healthcare spending to $4.3 trillion in 2021, signifying 18.3% of the GDP, with increased spending on Medicare and Medicaid. This rise in healthcare spending contributes to the growth of the hepatorenal syndrome treatment market.

A prominent trend in the hepatorenal syndrome treatment market is the increasing focus on research and development activities. Companies operating in this market are intensifying their efforts in research and development to maintain their market positions. For example, Mallinckrodt Pharmaceuticals, in September 2022, received FDA approval for Terlivaz, an injection to help adults with hepatorenal syndrome's kidney function, supported by the Phase 3 CONFIRM trial. This emphasis on research and development is vital for advancing treatment options for hepatorenal syndrome, resulting in improved patient outcomes.

Major companies in the hepatorenal syndrome treatment market are strategically focusing on advanced products such as hepatorenal drug solutions to enhance patient outcomes and address unmet medical needs. Hepatorenal drug solutions refer to innovative pharmaceuticals or treatments specifically designed to target and address the intricate pathology of hepatorenal syndrome. For instance, Ocelot Bio Inc., in August 2022, received orphan drug designation for its lead candidate OCE-205, addressing the urgent unmet medical needs of hepatorenal syndrome patients through a distinct mechanism of action. This strategic focus on advanced solutions contributes to improved efficacy and better management of hepatorenal syndrome, offering hope to patients with this complex condition affecting the liver and kidneys.

Major companies operating in the hepatorenal syndrome treatment market report are Becton Dickinson and Company, BioVie Inc., Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Orphan Therapeutics LLC, ESP Pharma Inc., PharmaIN Corporation, Baxter International Inc., La Jolla Pharmaceutical Company, Noorik Biopharmaceuticals AG, Novartis AG, Zydus Lifesciences limited, Mount Sinai Health System Inc., NYU Langone Health, Max Healthcare Institute Limited, 3A Composites, Ocelot Bio Inc., New Medicon Pharma Lab Private Limited, Allergan plc, Arrowhead Pharmaceuticals, Stealth BioTherapeutics Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Conatus Pharmaceuticals Inc., Catalyst Pharmaceuticals Inc., Bayer AG, Gilead Sciences Inc.

North America was the largest region in the hepatorenal syndrome treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global hepatorenal syndrome treatment market during the forecast period. The regions covered in the hepatorenal syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hepatorenal syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of hepatorenal syndrome treatment include type 1 hepatorenal syndrome and type 2 hepatorenal syndrome. Type 2 hepatorenal syndrome is characterized by a moderate and steady decline in glomerular filtration rate and commonly affects individuals whose liver function is still predominantly intact. Treatment involves the administration of therapeutics and, in some cases, surgical interventions. These treatments are utilized across various end-users, including hospitals and clinics, ambulatory surgical centers, academic and research institutes, among others.

The hepatorenal syndrome treatment market research report provides hepatorenal syndrome treatment optical components market statistics, including hepatorenal syndrome treatment optical components industry global market size, regional shares, competitors with a hepatorenal syndrome treatment optical components market share, detailed hepatorenal syndrome treatment optical components market segments, market trends and opportunities, and any further data you may need to thrive in the hepatorenal syndrome treatment optical components industry. This hepatorenal syndrome treatment optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatorenal syndrome treatment market includes revenues earned by providing imaging, blood, and urine tests to evaluate the patient's liver and kidney function. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products.


This product will be delivered within 3-5 business days.